The industry’s focus on living organisms of the human species and highly controlled standards create unique considerations for business leaders. These characteristics make the industry an ideal platform for innovation. They have resulted www.genotec-frankfurt.de/comparing-biotechnologically-engineered-nutritious-supplements/ in major breakthroughs in biofuels, crop yields, and life-saving pharmaceuticals.
When you think of strategies to generate revenue biotech start-ups have numerous options. The majority opt for a technology partnership or an asset creation and out-licensing strategy. Technology partnering provides faster revenue and lower risk of financial loss while an asset creation and out-licensing strategy can yield significantly more lucrative returns if it is successful. A growing number of biotechs in the research phase employ the hybrid approach, which combines the two approaches.
If you choose to go with a product-oriented approach can be successful commercially in the event that they manage to bring their pipelines to the right level, and attract a large pharmaceutical partner or a financier with deep pockets. It can be a costly proposition, however, and managing opportunistic approaches to leverage outside assets with the right research-based decision making about homegrown projects is key.
Alternatively, the “platform” model can provide an alternative way to earn revenue. It is a less expensive method than the development-oriented model but it comes with significant risk. In this model biotechs develop and own their platform technology before partnering with pharma companies to create a portfolio of drug-discovery projects that target specific diseases (i.e. disease x is a biological condition that causes). Advinus Therapeutics, among others have adopted this strategy.